Remdesivir versus Favipiravir in Hospitalized Patients with Moderate to Severe COVID-19 Pneumonia: A Propensity Score-Matched Retrospective Cohort Study.

Karuna ChavalertsakulYuda SutherasanTananchai PetnakKanin ThammavaranucuptSuppachok KirdlarpViboon BoonsarngsukSomnuek Sungkanuparph

Published in: International journal of general medicine (2024)

In patients with moderate to severe COVID-19 pneumonia, Remdesivir did not demonstrate superior benefits over Favipiravir regarding 29-day mortality, 15-day recovery rates, or hospital and ICU stay lengths. However, further investigation into the 15-day cumulative survival rate revealed a trend towards improved survival in the Remdesivir group.

Keyphrases

coronavirus disease
sars cov
high intensity
early onset
intensive care unit
free survival
healthcare
cardiovascular events
single cell
respiratory syndrome coronavirus
community acquired pneumonia
emergency department
respiratory failure
acute care